What is EKF Diagnostics Holdings Plc?
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally.
EKF · Verdict
Solid reward · low risk
EKF scores well on balance sheet and cash flow with no major weaknesses flagged in the model.
Based on 88% data coverage
EKF · Verdict
Interest covered 37.6×
23% free-cash-flow margin
Top decile vs peers
Above average
Model-based scoring. For information only — not financial advice.
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 109.29M, and a P/E ratio of 25.3x.
The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.